Thymosin alpha-1 is an unusual case in the peptide world. It is a real prescription medicine in many countries, yet it has never been approved by the FDA. That gap confuses a lot of people, so this post explains what the drug is, what the research shows and why "approved somewhere" is not the same as "approved here."
Key takeaways
- Thymosin alpha-1 is a 28-amino-acid peptide first found in the thymus, a gland that helps train immune cells.
- Its drug form, thymalfasin (brand name Zadaxin), is approved in more than 35 countries, mostly for chronic viral hepatitis and immune support.
- It is not FDA-approved in the US. US trials years ago did not lead to approval.
- Human research exists, but results are mixed and many studies are small or from a limited number of countries.
- Approval abroad does not make US "research use only" products safe. Talk to a licensed prescriber.
What thymosin alpha-1 is
The thymus sits behind your breastbone and is most active in childhood. It helps T cells, a key type of immune cell, mature. In the 1970s, researchers isolated several small proteins from thymus tissue and called them thymosins. Thymosin alpha-1 was one of them.
Lab studies suggest it acts on immune cells and signaling pathways that help the body respond to infections and tumors. The synthetic version is called thymalfasin. See the thymosin alpha-1 profile for a quick summary.
One common mix-up: thymosin alpha-1 is not the same as thymosin beta-4 or TB-500. Despite the shared name, they are different molecules. Our TB-500 explainer covers that one.
Where it is approved and for what
A 2020 review in the medical literature reported that thymalfasin is approved in more than 35 countries. Uses commonly listed include:
- Chronic hepatitis B
- Chronic hepatitis C
- Use as an immune enhancer in some other conditions, depending on the country
Each country's regulator makes its own decision based on its own review. The approved uses, forms and rules vary.
Why it is not approved in the US
Thymalfasin was studied in the US, including for hepatitis B. Those earlier trials produced limited results, and the drug was never approved. Later, the company received FDA orphan drug designations for some rare conditions, such as malignant melanoma. An orphan designation gives incentives to study a drug for a rare disease. It does not mean FDA has found the drug safe and effective.
Some articles online say thymosin alpha-1 is "FDA approved." Based on what we could verify, that is not correct. It has orphan designations, not approval.
What the human research shows
| Area | What studies suggest | Main limits |
|---|---|---|
| Chronic hepatitis B | Some trials and a meta-analysis compared it with interferon, with mixed results | Many small trials; older data |
| Sepsis | A multicenter trial in China reported lower death rates in one group | More large trials needed to confirm |
| Cancer (as an add-on) | Studied alongside other treatments in some cancers | Mostly early or small studies |
| COVID-19 | Several trials were registered in 2020; early reports were small | Strong evidence is lacking |
The fair reading is that thymosin alpha-1 has more human data than many trendy peptides, which is a real point in its favor. But the data are not strong enough for FDA approval in the US, and they do not support using it as a general "immune booster" in healthy people.
US compounding status
In September 2024, FDA removed thymosin alpha-1 from Category 2 of its interim compounding lists (substances that raise significant safety concerns) after its nominator withdrew the nomination. Its status for compounding has been under review since then, and the overall peptide compounding picture changed again in 2026.
Because these rules keep shifting, ask a licensed pharmacist what applies right now. Do not rely on a seller's website to tell you something is legal. Our post on 503A vs 503B compounding pharmacies explains how compounding fits in.
What "approved abroad" does and does not mean
Approval in another country tells you a regulator there reviewed the evidence and found it good enough for certain uses. That counts for something. It does not mean:
- The approval covers the uses promoted online, like general wellness or recovery
- A product sold online is the same approved, quality-checked medicine
- Your US doctor or pharmacist can legally supply it
Safety thoughts
In countries where it is approved, thymalfasin is generally described as well tolerated in studies. Still, some cautions apply:
- It acts on the immune system, so people with autoimmune disease, organ transplants or on immune-suppressing medicine need careful medical input.
- Little is known about use in pregnancy.
- Products sold online as "research use only" are not the approved drug. Purity, sterility and contents are not guaranteed.
If you are being treated with any peptide by a licensed prescriber, the PepSteady app can help you log doses and notes to share at follow-up visits.
The bottom line
Thymosin alpha-1 is a legitimate medicine in many countries, with more human research than most wellness peptides. It is still not FDA-approved in the US, and the evidence is mixed. If it interests you, have an honest talk with a licensed clinician and stay away from unregulated sources.
Sources
- Thymosin alpha 1: A comprehensive review of the literature (PMC)
- Comparison of the efficacy of thymosin alpha-1 and interferon alpha in chronic hepatitis B: a meta-analysis (NCBI Bookshelf)
- Zadaxin: Therapeutic Developed in United States Benefits Many in Asia (AUTM)
- FDA removes certain peptide bulk drug substances from Category 2 (Reed Smith)
Frequently asked questions
Is thymosin alpha-1 FDA-approved?
No. Thymosin alpha-1 (thymalfasin, sold abroad as Zadaxin) is not FDA-approved for any use in the United States. It has received some FDA orphan drug designations, which support research but are not an approval.
Where is thymosin alpha-1 approved?
A 2020 review reported that thymalfasin is approved in more than 35 countries, mainly for chronic hepatitis B and C and as an immune booster in certain conditions. Approval rules and uses differ from country to country.
Is thymosin alpha-1 the same as TB-500?
No. Thymosin alpha-1 and thymosin beta-4 (the source of TB-500) are different peptides with different structures and roles. TB-500 is also on the WADA Prohibited List, while thymosin alpha-1 is not named on it.